Retatrutide has generated more scientific discussion than any other metabolic peptide of the past decade. This guide provides UK researchers with a thorough technical overview: the mechanism of action, the published clinical evidence, and how it compares structurally and pharmacologically with other incretin-axis compounds.
What Is Retatrutide?
Retatrutide (INN: retatrutide; development code: LY3437943) is a synthetic peptide developed by Eli Lilly and Company. It is a triple agonist at three distinct G protein-coupled receptors:
- Glucagon-like peptide-1 receptor (GLP-1R)
- Glucose-dependent insulinotropic polypeptide receptor (GIPR)
- Glucagon receptor (GCGR)
This triple-receptor activity profile distinguishes it from all previously approved or clinically advanced incretin-based compounds. It is currently in Phase III clinical evaluation under the TRIUMPH programme.
The peptide comprises 39 amino acids with a C18 fatty acid modification at an internal lysine residue. This structural feature extends the plasma half-life to approximately 6 days, enabling a once-weekly dosing regimen in clinical models.
The Mechanism of Action: Why Triple Agonism Matters
To understand what makes retatrutide scientifically significant, it helps to understand what each receptor system does:
GLP-1 receptor (GLP-1R)
GLP-1 (glucagon-like peptide-1) is a gut-derived hormone released in response to food intake. GLP-1R activation:
- Stimulates glucose-dependent insulin secretion from pancreatic beta cells
- Suppresses glucagon secretion from alpha cells
- Slows gastric emptying (promoting satiety)
- Acts centrally to reduce appetite via hypothalamic pathways
This is the target of approved drugs including semaglutide (Ozempic/Wegovy) and the GLP-1 component of tirzepatide (Mounjaro).
GIP receptor (GIPR)
GIP (glucose-dependent insulinotropic polypeptide) is the second major incretin hormone. GIPR activation:
- Potentiates insulin secretion synergistically with GLP-1R activity
- Promotes adipocyte lipid storage (this effect is dose and context dependent)
- May modulate energy expenditure in adipose tissue
Tirzepatide (a dual GLP-1/GIP agonist) achieves superior weight reduction compared to GLP-1-only agonists partly through this synergistic effect.
Glucagon receptor (GCGR)
Glucagon is primarily known as the counter-regulatory hormone that raises blood glucose by stimulating hepatic glycogenolysis and gluconeogenesis. However, at the receptor level, GCGR activation in the context of concurrent GLP-1R agonism has different effects:
- Increased hepatic fatty acid oxidation — the liver burns more fat as fuel
- Increased thermogenesis — elevated energy expenditure at rest
- Reduced hepatic fat accumulation — significant reduction in steatosis markers
This hepatic effect is the key mechanistic addition that retatrutide brings over dual agonists. It is why retatrutide demonstrates superior preclinical effects on non-alcoholic steatohepatitis (NASH) markers compared to GLP-1/GIP-only compounds.
The NEJM 2023 Phase II Study: Key Data
The landmark publication is:
Jastreboff AM et al., “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial”, New England Journal of Medicine, Volume 389, pages 514–526 (2023). DOI: 10.1056/NEJMoa2301972
Study design
- Randomised, double-blind, placebo-controlled Phase II trial
- 338 adults with BMI ≥30 (or ≥27 with weight-related comorbidity)
- 25 centres across the United States
- 48-week treatment period plus 28-week follow-up
- Five dose arms: 1 mg, 4 mg, 8 mg, and 12 mg weekly retatrutide, plus placebo
Primary results at 48 weeks
| Dose | Mean Weight Change | ≥5% Responders | ≥10% Responders |
|---|---|---|---|
| Placebo | -2.1% | 27% | 10% |
| 1 mg | -8.7% | 75% | 48% |
| 4 mg | -17.1% | 93% | 83% |
| 8 mg | -22.8% | 100% | 94% |
| 12 mg | -24.2% | 100% | 96% |
The 12 mg dose group showed a mean weight reduction of -24.2% — the strongest efficacy signal documented for any single therapeutic agent in a randomised clinical trial to that point.
Secondary endpoints
Beyond weight reduction, the study documented:
- HbA1c reduction of -1.3% in the 12 mg group (among participants with elevated baseline HbA1c)
- Fasting plasma glucose reduced by 18%
- Systolic blood pressure reduced by 7.2 mmHg
- Triglycerides reduced by 30%
- hsCRP (high-sensitivity C-reactive protein) reduced by 42%
The TRIUMPH Phase III Programme
Following the Phase II results, Eli Lilly initiated the TRIUMPH programme — a suite of Phase III trials:
- NCT05929066 — retatrutide for chronic weight management in adults with obesity
- NCT05929079 — retatrutide in adults with obesity and type 2 diabetes
The programme is recruiting at 45+ centres worldwide and involves >4,000 participants across multiple countries. Results are anticipated from 2026 onwards.
Structural Chemistry
Retatrutide’s 39-amino-acid sequence is related to oxyntomodulin and glucagon, with modifications optimised for triple-receptor agonism. Key structural features:
- C18 fatty acid chain attached via a gamma-glutamic acid linker to a mid-sequence lysine residue — this “palmitoylation” strategy (similar to that used in semaglutide) enables albumin binding, extending half-life from hours (for unmodified peptide) to approximately 6 days
- Alanine substitution at position 2 — prevents rapid degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme responsible for rapid inactivation of natural GLP-1
- GLP-1R affinity: EC50 ≈ 0.1 nM (high affinity)
- GIPR and GCGR affinities are optimised to achieve a balanced agonist profile across all three receptors
Comparison with Other Incretin Peptides
For UK researchers contextualising retatrutide within the broader incretin peptide research landscape:
| Compound | Receptors | Class | Phase II Weight Loss | Status (2026) |
|---|---|---|---|---|
| Semaglutide | GLP-1R | Monoagonist | ~15% | Approved (Wegovy) |
| Tirzepatide | GLP-1R + GIPR | Dual agonist | ~22% | Approved (Mounjaro) |
| Retatrutide | GLP-1R + GIPR + GCGR | Triple agonist | -24.2% | Phase III |
The progressive increase in efficacy from mono → dual → triple agonism reflects the additive metabolic effects of targeting multiple receptor systems simultaneously.
Note: Semaglutide and tirzepatide are approved medicines. They are not research chemicals and are not available from RUO suppliers. This comparison is provided for scientific context only.
Preclinical Data (Coskun et al., Cell Metabolism 2022)
Complementing the clinical data, Coskun et al. published preclinical mechanistic studies:
Coskun T et al., “LY3437943, a novel triple GIP, GLP-1 and glucagon receptor agonist for glycaemic control and weight loss”, Cell Metabolism, Volume 34, pages 1234–1247 (2022). DOI: 10.1016/j.cmet.2022.07.013
Key preclinical findings include:
- Hepatic fat content reduced by up to 80% in diet-induced obesity (DIO) mouse models
- Significant reduction in ALT and AST (markers of liver inflammation)
- Enhanced hepatic lipid oxidation — consistent with the predicted GCGR-mediated mechanism
- Improved skeletal muscle insulin sensitivity
Storage and Reconstitution for Research
Retatrutide for research is supplied as lyophilised powder in sealed glass vials.
Storage (lyophilised):
- Stable at -20°C for 18 months
- Protect from light and moisture
Reconstitution:
- Recommended solvent: Bacteriostatic Water (0.9% benzyl alcohol)
- Add 1–2 mL to a 10 mg vial
- Concentration: 10 mg/mL at 1 mL; 5 mg/mL at 2 mL
- Reconstituted solution: stable at 2–8°C for 28 days
Availability in the UK
Retatrutide is available as a research compound from UK Peptides with:
-
99% HPLC analytical purity
- EU warehouse stock for fast UK delivery
- Full RUO labelling
- Available in 10 mg, 20 mg, and 30 mg vials
This article is for research information only.
All products are Research Use Only. Not for human consumption. Retatrutide is not an approved medicine in any jurisdiction.